Angela Walsh
Senior Vice President of Finance and Treasurer
Replay available
Virios Therapeutics, Inc. (VIRI) Q2 2024 Earnings Call
Virios Therapeutics, Inc. (NASDAQ: VIRI) Q2 2024 earnings conference call, held 2024-08-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
David Bouts
Analyst, Zacks Small Cap Research
Greg Duncan
Chief Executive Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Dogwood Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.009 -- 00:00:05.373 Good morning, and welcome to the Vireos Therapeutics Incorporated first quarter 2024 00:00:05.373 -- 00:00:06.814 earnings 00:00:06.814 -- 00:00:08.535 call. 00:00:08.535 -- 00:00:13.218 At this time, all participants have been placed on a listen-only mode. 00:00:13.218 -- 00:00:18.922 Please be advised that today's call is being recorded at the company's request. 00:00:18.922 -- 00:00:23.966 At this time, I'd like to turn the call over to Angela Walsh, Senior Vice President 00:00:23.966 -- 00:00:27.848 of Finance and Treasurer for Vireos Therapeutics. 00:00:27.848 -- 00:00:30.509 Please proceed, Angela. 00:00:30.523 -- 00:00:35.006 Good morning, everyone, and thank you for joining us on today's conference call. 00:00:35.006 -- 00:00:39.970 We are pleased to be with you today to discuss various therapeutics first quarter financial 00:00:39.970 -- 00:00:43.312 results and to provide a corporate update. 00:00:43.312 -- 00:00:48.676 Please note that our financial results press release is now available on our website. 00:00:48.676 -- 00:00:53.859 Before we begin, I'd like to remind everyone that statements made during this conference 00:00:53.859 -- 00:00:59.771 call will include forward-looking statements within the meaning of the Private Securities 00:00:59.771 -- 00:01:03.072 Litigation Reform Act of 1995, 00:01:03.072 -- 00:01:08.174 which involved risks and uncertainties that can cause actual results to differ 00:01:08.174 -- 00:01:14.396 materially from the information expressed or implied by these forward-looking statements. 00:01:14.396 -- 00:01:19.458 For more information regarding such risks and uncertainties, please see the 00:01:19.458 -- 00:01:23.679 risk factors outlined in the company's filings with the SEC. 00:01:23.679...